The Effects of Sidt2 on the Inflammatory Pathway in Mouse Mesangial Cells

Hui Sun1,2, Jia-Ming Ding3, Hui-Hao Zheng4

  • 1Department of Endocrinology and Genetic Metabolism, Yijishan Hospital of Wannan Medical College, Wuhu 241002, China.

Insights

Inhibition of SID1 transmembrane family member 2 (Sidt2) in mouse mesangial cells exacerbated inflammation and cell damage. Sidt2 deficiency activates key inflammatory pathways, suggesting Sidt2 plays a protective role in kidney disease.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Immunology

Background:

  • Chronic kidney disease (CKD) is characterized by inflammatory pathways contributing to renal fibrosis and function decline.
  • Targeting inflammatory signaling pathways is crucial for CKD treatment.
  • The role of SID1 transmembrane family member 2 (Sidt2) in inflammation remains largely unexplored.

Purpose of the Study:

  • To investigate the effect of Sidt2 on inflammation in mouse mesangial cells.
  • To determine the role of Sidt2 in regulating inflammatory signaling pathways.
  • To explore Sidt2 as a potential therapeutic target for CKD.

Main Methods:

  • Utilized a lentiviral CRISPR/Cas9 vector to inhibit Sidt2 gene expression in a mouse mesangial cell line.
  • Performed Hematoxylin and eosin staining and microscopy to assess cell morphology.
  • Analyzed the expression levels of key proteins in the NF-κB, Jak/Stat, and MAPK inflammatory pathways.

Main Results:

  • Sidt2 inhibition led to altered mesangial cell morphology, with smaller cell bodies and nuclear fragmentation.
  • Deletion of Sidt2 upregulated inflammatory markers in the NF-κB, Jak/Stat, and MAPK pathways.
  • LPS stimulation further amplified these inflammatory responses in Sidt2-deficient cells, indicating Sidt2's protective role.

Conclusions:

  • Sidt2 deficiency significantly impacts inflammatory signaling pathways, including NF-κB, Jak/Stat, and MAPK.
  • The absence of Sidt2 exacerbates inflammatory responses and contributes to glomerular mesangial cell damage.
  • Sidt2 may serve as a potential therapeutic target for mitigating inflammation in CKD.

Related Concept Videos